Gastroenterol Res

Gastroenterology Research, ISSN 1918-2805 print, 1918-2813 online, Open Access

Article copyright, the authors; Journal compilation copyright, Gastroenterol Res and Elmer Press Inc

Journal website http://www.gastrores.org

Original Article

Volume 8, Number 6, December 2015, pages 296-302

Nodule Regression in Adults With Nodular Gastritis

**Table 1.** Baseline Characteristics of the Included Subjects
Characteristics	NG patients (n = 117)
SD: standard deviation; UGI: upper gastrointestinal.
Age (years, mean ± SD)	38.3 ± 8.0
Gender (female, %)	86 (73.5%)
Follow-up period (months, mean ± SD)	32.0 ± 14.7
Presence of UGI symptom (%)
Epigastric pain	8 (6.8%)
Indigestion	5 (4.3%)
Abdominal distention	2 (1.7%)
Nausea	2 (1.7%)
Size of the nodules (%)
Small granular-type	64 (54.7%)
Large nodular-type	53 (45.3%)
Location of the nodules (%)
Antrum only	73 (62.4%)
Body involved	44 (37.6%)
Presence of hemorrhagic spots (%)	21 (17.9%)
H. pylori eradication (%)	18 (15.4%)
Pathology based on the updated Sydney system
Inflammation (none/mild/moderate/marked)	0:5:91:21
Activity (none/mild/moderate/marked)	5:42:61:9
Atrophy (none/mild/moderate/marked)	91:22:4:0
Intestinal metaplasia (none/mild/moderate/marked)	106:10:0:1
H. pylori (none/mild/moderate/marked)	6:10:48:53

Table 1. Baseline Characteristics of the Included Subjects

Characteristics

NG patients (n = 117)

SD: standard deviation; UGI: upper gastrointestinal.

Age (years, mean ± SD)

38.3 ± 8.0

Gender (female, %)

86 (73.5%)

Follow-up period (months, mean ± SD)

32.0 ± 14.7

Presence of UGI symptom (%)

Epigastric pain

8 (6.8%)

Indigestion

5 (4.3%)

Abdominal distention

2 (1.7%)

Nausea

2 (1.7%)

Size of the nodules (%)

Small granular-type

64 (54.7%)

Large nodular-type

53 (45.3%)

Location of the nodules (%)

Antrum only

73 (62.4%)

Body involved

44 (37.6%)

Presence of hemorrhagic spots (%)

21 (17.9%)

H. pylori eradication (%)

18 (15.4%)

Pathology based on the updated Sydney system

Inflammation (none/mild/moderate/marked)

0:5:91:21

Activity (none/mild/moderate/marked)

5:42:61:9

Atrophy (none/mild/moderate/marked)

91:22:4:0

Intestinal metaplasia (none/mild/moderate/marked)

106:10:0:1

H. pylori (none/mild/moderate/marked)

6:10:48:53

**Table 2.** Correlation Analysis of the Variables on Nodule Regression
Variables	Correlation coefficient	P-value
Age	0.044	0.637
Gender	0.072	0.437
Follow-up period	-0.200	0.030
Presence of upper gastrointestinal symptom	-0.250	0.007
Size of the nodules	0.202	0.029
Location of the nodules	0.133	0.152
Presence of hemorrhagic spots	0.103	0.271
H. pylori eradication	-0.541	< 0.001
Pathology findings based on the updated Sydney system
Inflammation	0.142	0.127
Activity	-0.088	0.345
Atrophy	-0.027	0.773
Intestinal metaplasia	-0.153	0.099
H. pylori infiltration	-0.012	0.899

Table 2. Correlation Analysis of the Variables on Nodule Regression

Variables

Correlation coefficient

P-value

Age

0.044

0.637

Gender

0.072

0.437

Follow-up period

-0.200

0.030

Presence of upper gastrointestinal symptom

-0.250

0.007

Size of the nodules

0.202

0.029

Location of the nodules

0.133

0.152

Presence of hemorrhagic spots

0.103

0.271

H. pylori eradication

-0.541

< 0.001

Pathology findings based on the updated Sydney system

Inflammation

0.142

0.127

Activity

-0.088

0.345

Atrophy

-0.027

0.773

Intestinal metaplasia

-0.153

0.099

H. pylori infiltration

-0.012

0.899

**Table 3.** Comparison Between the Patients With Nodule Regression and Those With Persistent Nodules at the Follow-Up Tests
Variables	Patients with nodule regression (n = 21)	Patients with persistent nodules (n = 96)	P-value
SD: standard deviation; UGI: upper gastrointestinal.
Age (years, mean ± SD)	37.6 ± 8.5	38.5 ± 7.9	0.637
Gender (female, %)	14 (66.7%)	72 (75.0%)	0.433
Presence of UGI symptom (%)	7 (33.3%)	10 (10.4%)	0.007
Size of the nodules (%)			0.029
Small granular-type	16 (76.2%)	48 (50.0%)
Large nodular-type	5 (23.8%)	48 (50.0%)
Location of the nodules (%)			0.214
Antrum only	16 (76.2%)	57 (59.4%)
Body involved	5 (23.8%)	39 (40.6%)
Presence of hemorrhagic spots (%)	2 (9.5%)	19 (19.8%)	0.267
Pathology scores (0:1:2:3)
Inflammation	0:2:17:2	0:3:74:19	0.260
Activity	0:7:12:2	5:35:49:7	0.711
Atrophy	17:2:2:0	74:20:2:0	0.136
Intestinal metaplasia	18: 2:0:1	88:8:0:0	0.097
H. pylori	1:1:10:9	5:9:38:44	0.864
H. pylori eradication (%)	12 (57.1%)	6 (6.2%)	< 0.001
Follow-up period (months, mean ± SD)	38.2 ± 12.1	30.6 ± 14.9	0.030

Table 3. Comparison Between the Patients With Nodule Regression and Those With Persistent Nodules at the Follow-Up Tests

Variables

Patients with nodule regression (n = 21)

Patients with persistent nodules (n = 96)

P-value

SD: standard deviation; UGI: upper gastrointestinal.

Age (years, mean ± SD)

37.6 ± 8.5

38.5 ± 7.9

0.637

Gender (female, %)

14 (66.7%)

72 (75.0%)

0.433

Presence of UGI symptom (%)

7 (33.3%)

10 (10.4%)

0.007

Size of the nodules (%)

0.029

Small granular-type

16 (76.2%)

48 (50.0%)

Large nodular-type

5 (23.8%)

48 (50.0%)

Location of the nodules (%)

0.214

Antrum only

16 (76.2%)

57 (59.4%)

Body involved

5 (23.8%)

39 (40.6%)

Presence of hemorrhagic spots (%)

2 (9.5%)

19 (19.8%)

0.267

Pathology scores (0:1:2:3)

Inflammation

0:2:17:2

0:3:74:19

0.260

Activity

0:7:12:2

5:35:49:7

0.711

Atrophy

17:2:2:0

74:20:2:0

0.136

Intestinal metaplasia

18: 2:0:1

88:8:0:0

0.097

H. pylori

1:1:10:9

5:9:38:44

0.864

H. pylori eradication (%)

12 (57.1%)

6 (6.2%)

< 0.001

Follow-up period (months, mean ± SD)

38.2 ± 12.1

30.6 ± 14.9

0.030

**Table 4.** Significant Variables Related to Nodule Regression
Variables	Odds ratio	95% confidence interval	P-value
*Cut-off value was determined by the ROC curve analysis.
H. pylori eradication
No (persistent H. pylori infection)	0.020	0.003 - 0.137	< 0.001
Yes	1 (reference)
Follow-up period*
< 30.5 months	0.140	0.028 - 0.700	0.017
≥ 30.5 months	1 (reference)
Upper gastrointestinal symptom
Present	1.483	0.246 - 8.936	0.667
Absent	1 (reference)
Size of the nodules
Small	2.670	0.738 - 9.658	0.134
Large	1 (reference)

Table 4. Significant Variables Related to Nodule Regression

Variables

Odds ratio

95% confidence interval

P-value

*Cut-off value was determined by the ROC curve analysis.

H. pylori eradication

No (persistent H. pylori infection)

0.020

0.003 - 0.137

< 0.001

Yes

1 (reference)

Follow-up period*

< 30.5 months

0.140

0.028 - 0.700

0.017

≥ 30.5 months

1 (reference)

Upper gastrointestinal symptom

Present

1.483

0.246 - 8.936

0.667

Absent

1 (reference)

Size of the nodules

Small

2.670

0.738 - 9.658

0.134

Large

1 (reference)